Cerevel Therapeutics Announces Strategic $125 Million Non-Dilutive Financing Transaction for Tavapadon

Cerevel Therapeutics Announces Strategic $125 Million Non-Dilutive Financing Transaction for Tavapadon

Submitted by admin on April 13, 2021 - 10:17am
Source: 
BioSpace
News Tags: 
Cerevel Therapeutics
Parkinson's Disease
tavapadon
Bain Capital
Novaquest
Headline: 
Cerevel Therapeutics Announces Strategic $125 Million Non-Dilutive Financing Transaction for Tavapadon
snippet: 

Risk-sharing arrangement with NovaQuest and Bain Capital will fund the full tavapadon Phase 3 development program for Parkinson’s disease through planned NDA submission

Do Not Allow Advertisers to Use My Personal information